A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Inclusion Criteria:

• Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening

• Documented history of inadequate response to treatment with topical medication forat least 4 weeks, unless topical treatments are otherwise medically inadvisable, orhas required systemic therapy for control of disease

• All the following must be present to confirm moderate-to-severe AD

• Eczema Area and Severity Index score ≥ 12 (at Screening and Day 1)

• Body Surface Area ≥ 10% (at Screening and Day 1)

• Validated Investigator Global Assessment for Atopic Dermatitis ≥ 3 (atScreening and Day 1)

• Peak Pruritus Numerical Rating Scale ≥ 4 (at Screening)

Exclusion Criteria:

• Evidence of an active and/or concurrent inflammatory skin condition that wouldinterfere with the Investigator or subject-driven evaluations of AD

• Any major surgery within the last 30 days before the first dose of studyintervention, or any surgery planned during the course of the study

• Any other sound medical, psychiatric, and/or social reason as determined by theinvestigator

Other protocol-defined inclusion/exclusion criteria apply